We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Low Cost Device Helps Diagnose Pancreatic Cancer

By LabMedica International staff writers
Posted on 20 Feb 2014
A low-cost device has been developed that could help pathologists diagnose pancreatic cancer earlier and faster.

The prototype microfluidic device can perform the basic steps for processing a biopsy, relying on fluid transport instead of human hands to process the tissue. More...


Scientists and engineers at the University of Washington (Seattle, WA, USA) have developed instrumentation that would essentially automate and streamline the manual, time-consuming process a pathology laboratory goes through to diagnose cancer. The technology would process and analyze whole tissue biopsies for three-dimensional (3-D) imaging, which offers a more complete picture of the cellular makeup of a tumor.

The team built a thick, credit card-sized, flexible device out of silicon that allows a piece of tissue to pass through tiny channels and undergo a series of steps that replicate what happens on a much larger scale in a pathology laboratory. The device harnesses the properties of microfluidics, which allows tissue to move and stop with ease through small channels without needing to apply a lot of external force. It also saves clinicians from having to handle the actual specimen as a tissue biopsy taken with a syringe needle could be deposited directly into the device to begin processing.

The investigators say this is the first time material larger than a single-celled organism has successfully moved in a microfluidic device. This could have implications across the sciences in automating analyses that usually are done by humans. The team first built a mold using a petri dish and Teflon tubes, and then poured a viscous, silicon material into the mold. The result is a small, transparent instrument with seamless channels that are both curved and straight.

Ronnie Das, PhD, the lead author of the study said, “As soon as you cut a piece of tissue, you lose information about it. If you can keep the original tissue biopsy intact, you can see the whole story of abnormal cell growth. You can also see connections, cell morphology and structure as it looks in the body.” The technology could be used overseas as a kit that would process biopsies, and then send that information to pathologists who could look for signs of cancer from remote locations.
Additionally, it could potentially reduce the time it takes to diagnose cancer to a matter of minutes. The study was presented at the International Society for Optics and Photonics (SPIE Photonics West) conference held February 1-6, 2014, in San Francisco (CA, USA).

Related Links:

University of Washington



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.